Similar articles for PMID: 31638667

Year	Number of Results
2010	1
2012	5
2013	4
2014	11
2015	16
2016	23
2017	21
2018	13
2019	12
2020	5
2021	3
2022	2
2023	1
2024	0

1

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.

McCaw ZR, Wei LJ. McCaw ZR, et al. JAMA. 2019 Oct 22;322(16):1607. doi: 10.1001/jama.2019.13159. JAMA. 2019. PMID: 31638667 No abstract available.

2

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply.

Hahn JY, Song YB, Gwon HC. Hahn JY, et al. JAMA. 2019 Oct 22;322(16):1607-1608. doi: 10.1001/jama.2019.13163. JAMA. 2019. PMID: 31638672 No abstract available.

3

Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.

Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP, Siller-Matula JM. Winter MP, et al. Eur Heart J Cardiovasc Pharmacother. 2017 Oct 1;3(4):221-234. doi: 10.1093/ehjcvp/pvw044. Eur Heart J Cardiovasc Pharmacother. 2017. PMID: 28204303 Review.

4

Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Dayoub EJ, et al. JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783. JAMA Intern Med. 2018. PMID: 29799992 Free PMC article.

5

Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Marcano AL, Ferreiro JL. Marcano AL, et al. Curr Atheroscler Rep. 2016 Nov;18(11):66. doi: 10.1007/s11883-016-0617-y. Curr Atheroscler Rep. 2016. PMID: 27714642 Review.

6

Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.

Song YB, Oh SK, Oh JH, Im ES, Cho DK, Cho BR, Lee JY, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC, Hahn JY. Song YB, et al. Am Heart J. 2018 Mar;197:77-84. doi: 10.1016/j.ahj.2017.12.002. Epub 2017 Dec 6. Am Heart J. 2018. PMID: 29447787

7

Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.

Tang J, Li MP, Zhou HH, Chen XP. Tang J, et al. Curr Vasc Pharmacol. 2015;13(5):566-77. doi: 10.2174/1570161112666141127162209. Curr Vasc Pharmacol. 2015. PMID: 25440595 Review.

8

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.

Zhou Y, Wang Y, Wu Y, Huang C, Yan H, Zhu W, Xu W, Zhang L, Zhu J. Zhou Y, et al. BMC Cardiovasc Disord. 2017 Jun 15;17(1):157. doi: 10.1186/s12872-017-0582-6. BMC Cardiovasc Disord. 2017. PMID: 28619104 Free PMC article.

9

[Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome].

SHalaev SV, Safiullina ZM. SHalaev SV, et al. Kardiologiia. 2018 Mar;(3):54-62. Kardiologiia. 2018. PMID: 29782272 Clinical Trial. Russian.

10

Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention.

Choudhary R, Kumari V. Choudhary R, et al. Am Heart J. 2020 Dec;230:99. doi: 10.1016/j.ahj.2020.09.002. Am Heart J. 2020. PMID: 33248476 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year